Power

in patient management

Introducing a more sensitive, accurate, standardized assay to detect clonality in cancers and minimal residual disease in lymphoid malignancies.

What it is

A clinical assay to measure lymphoid clonality and distribution in a range of diseases. Significantly more sensitive than today’s most common pathology tests, the results help doctors determine effectiveness of treatments, monitor patient remission status, and personalize future treatments.

Highlights

  • A set of CLIA-standardized assays for highly sensitive (approximately 10-6) detection of MRD in patients with lymphoid malignancies.
  • Offers high-data quality with built-in error checking during and following sequence generation, and unsurpassed reduction of PCR bias based on the development of unique molecular and computational tools
  • Use to monitor post treatment MRD when a clonal or oligoclonal sequence marker of the malignant cell has been established
  • Hematologic malignancies that would benefit:
    • T-Acute Lymphoblastic Leukemia
    • B-Acute Lymphoblastic Leukemia
    • Chronic Lymphocytic Leukemia
    • T cell or B cell Lymphomas
    • Multiple Myeloma
  • Also defines clonality, diversity, and distribution of lymphoid infiltrates in other cancers

Example Reports

Easy to read and interpret clinical report suitable for inclusion in a patient medical record

Clonal Diagnostic Report

Highlights

1

Patient Identifiers (HIPAA compliant)

2

Bar graph display of all sequences >5%

3

Nucleotide detail of “diagnostic” sequences

4

Interpretation

5

Summary statement


Minimal Residual Disease Report

Highlights

1

Patient identifiers (HIPAA compliant)

2

Diagnostic sequences being tracked and frequency at diagnosis

3

Is there evidence of residual disease (YES/NO)?

4

How many residual malignant cells per 1,000,000 total nucleated cells in the sample (upper bound of 95% confidence interval)

5

Graphic display of frequency of “marker” sequences. Also used to display trend of marker sequences over time since diagnosis

How It Works

Easy-to-follow process adapts to your needs and delivers results in 7 days.

Click on each icon for more details.

Order

If this is your first order, please review the following:

Adaptive adapts to your ordering needs

Option 1: Integrate with your laboratory information system (LIS)

Integrate clonoSEQ into your institution’s laboratory information system where ordering is as simple as logging in and completing the order form. Contact us for assistance with this process at 855-466-8667.

Option 2: Set up an individual account

Complete the account registration form on the Order page. Each physician who will place an order needs to submit a form. Once the form has been approved, you'll just need to fill out the short order form for each patient sample sent. Securely fax your order to Adaptive at: 866-224-1645

Set Up Individual Account

Sample

Adaptive adapts to your clinical sample collection needs

Overview

  • Sample Types Accepted:
    • Blood
    • Bone Marrow Aspirate
    • DNA (call Adaptive to arrange)
  • As little as 4mL of blood
  • As little as 200ul of bone marrow aspirate
  • Simply draw or transfer to any EDTA (preferred), ACD (preferred), or Heparin vacutainer

Download Sample Preparation Guidelines

Ship

Adaptive adapts to your clinical shipping needs

Overview

  • Use own shipping department OR
  • Use Adaptive’s shipping boxes: Options for postage paid shipping mean choice and convenience
  • Simply ship samples overnight express on ambient packs using your own materials or Adaptive shipping boxes. The choice is yours!

Sequence

Our lab performs high-throughput sequence analysis on your patient samples

Overview

The clonoSEQ assay focuses on the T cell receptor or B cell receptor (Ig) Complementarity Determining Region 3 (CDR3) area. The nucleotide sequences that encode the CDR3 regions are generated by site-specific recombination between genomic variable (V), diversity (D), and joining (J) region gene segments (Figure A).

Because of the inherent diversity of receptors that are formed, it is highly improbable that the same CDR3 nucleotide sequence will be independently created twice, effectively making each CDR3 sequence a unique nucleotide tag for any specific T cell or B cell and its clonal descendants (Figure B ).

This unique nucleotide tag (Figure C ) is the marker utilized to track the malignant T or B cell over time via a proprietary multiplex PCR technology paired with next-generation sequencing and refined computational analysis.

Order

Questions? Call: 855-466-8667

Back to Top